Compare Amgen, Inc. (AMGN) vs Invesco DB Oil Fund (DBO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Invesco DB Oil Fund — how do they compare? Amgen, Inc. trades at $360.87 (market cap $196.12B), while Invesco DB Oil Fund trades at $18.58. The key difference: Amgen, Inc. pays a 2.77% dividend while Invesco DB Oil Fund pays none, and Amgen, Inc. is trading nearer its 52-week high, Invesco DB Oil Fund nearer its low. Which is the better fit depends on your goals.
| AMGN | DBO | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | Commodities - Energy |
52-Week High | $388.16 | $23.80 |
52-Week Low | $271.18 | $11.98 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
DBO trades at $18.06, down 0.44% with neutral technical signals amid volatile oil market conditions. The stock shows bearish moving averages but neutral oscillators, with key support at $18 and resistance at $19. Recent oil price volatility driven by geopolitical tensions creates both opportunities and risks for energy sector stocks.
The outlook remains balanced with oil market fundamentals showing mixed signals - supply constraints from geopolitical events versus potential demand concerns. Investment opportunity exists if oil prices sustain recent gains, while risks include Middle East volatility and potential demand deterioration. The stock's technical positioning suggests range-bound trading near current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Invesco DB Oil Fund
DBO provides exposure to WTI crude oil prices through futures contracts. It is designed for investors seeking a way to invest in the performance of the fossil fuel market without purchasing physical oil barrels.
Read more on DBO →
